Related Experiment Video

Updated: Aug 5, 2026

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies

Dayna Smith1, Anudishi Tyagi2, Venkata Lokesh Battula2

  • 1Research Institute of Molecular Pathology, Vienna, Austria.

Frontiers in Immunology
|August 1, 2026
PubMed

Insights

Immune checkpoint protein B7-H3 (CD276) shows promise as a cancer immunotherapy target due to its overexpression in many cancers. Further research into B7-H3 mechanisms and pathways is crucial for advancing cancer therapies.

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • Immune checkpoint protein B7-H3 (CD276) is increasingly recognized as a significant target in cancer immunotherapy.
  • B7-H3 is overexpressed across various cancer types and is frequently linked to adverse patient prognoses.
  • Its precise receptor remains unidentified, yet B7-H3 plays a role in multiple tumor progression mechanisms.

Purpose of the Study:

  • To provide an updated review of the current knowledge on immune checkpoint protein B7-H3.
  • To summarize ongoing cancer therapies targeting B7-H3.
  • To highlight B7-H3's potential as a cancer immunotherapy target and identify areas for future research.

Main Methods:

  • Literature review of existing studies on B7-H3.
  • Analysis of clinical trial data for B7-H3 targeted therapies.
  • Synthesis of information on B7-H3's role in tumor progression and its biomarker potential.

Main Results:

  • B7-H3 is a promising target for cancer immunotherapy, with numerous clinical trials in progress.
  • Overexpression of B7-H3 correlates with poor prognosis in many cancer types.
  • Despite its therapeutic potential, the regulatory mechanisms and receptor interactions of B7-H3 require further elucidation.

Conclusions:

  • B7-H3 demonstrates significant promise as a target for novel cancer immunotherapies.
  • Continued investigation into B7-H3's biological functions and therapeutic targeting is essential.
  • Advancements in understanding B7-H3 pathways could lead to improved cancer treatment strategies.
Keywords:
B7-H3CAR-T cells and bispecific antibodiesantibody-drug conjugates (ADCs)cancer immunotherapyimmune checkpoint protein (ICP)

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...